CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 43 enrolled
Drug / intervention
Glucagon stimulation test and insulin tolerance test +1 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01282164
NCT01282164N/ACompleted
CompareCT.gov

The Diagnostic Accuracy of the Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and the Hypothalamic-Pituitary-Adrenal Axis

The Cleveland Clinic·interventional·Posted Jan 24, 2011·Updated May 17, 2017

In Brief

A clinical study evaluating Glucagon stimulation test and insulin tolerance test and glucagon stimulation test and insulin tolerance test for Adult Growth Hormone Deficiency and Hypothalamic-pituitary Disorders. Completed, enrolled 43 participants across 4 sites.

Detailed Summary

The purpose of this study is to find out if the Glucagon Stimulation Test (GST) is a reliable alternative to the Insulin Tolerance Test (ITT) for diagnosis of Growth Hormone Deficiency (GHD) and adrenal insufficiency. In some patients the accuracy of the GST for evaluation of adrenal insufficiency is compared to the adrenocorticotropin hormone (ACTH ) stimulation test.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Growth Hormone Deficiency, Hypothalamic-pituitary Disorders
CountriesUnited States
CollaboratorsMassachusetts General Hospital, Allegheny Endocrinology Associates, Oregon Health and Science University

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 24, 2011
Enrollment StartJan 1, 2011
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 15.4 years ago

Interventions

Glucagon stimulation test and insulin tolerance testprocedure

glucagon stimulation test using 1 mg (1.5 mg if weigh \>90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), cerebrovascular disease (CVD), seizure

glucagon stimulation test and insulin tolerance testprocedure

glucagon stimulation test using 1 mg (1.5 mg if weigh \>90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), CVD (cerebrovascular disease), seizure